Research-based global biopharmaceutical company AbbVie (NYSE:ABBV) and pharmaceutical company Allergan (NYSE:AGN) revealed on Monday that Allergan has signed definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) in the first-quarter 2020.

The agreements are reportedly part of the ongoing regulatory approval process for AbbVie's acquisition of Allergan subject to receipt of required regulatory approvals and other closing conditions, including the FTC and European Commission approvals.

Under the terms of an agreement, AstraZeneca (NYSE:AZN) will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Pursuant to the agreement, Nestle (Swiss:NESN) will acquire and take full operational ownership of Zenpep upon closing and customary transition support from Allergan. Zenpep is a treatment available in the US for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestle will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

Both the acquisitions of brazikumab and Zenpep are contingent upon receipt of US Federal Trade Commission and European Commission approval, closing of AbbVie's pending acquisition of Allergan as well as the satisfaction of other customary closing conditions.